Major FoB Collaborations
[Updated footnote re Celltrion/HSP and Remicade.]
Items are shown in reverse chronological order.
Date Targets Geography iHub References
Oncobiolgcs-Huahai 5/13 # global #msg-87734336, #msg-87744882
Strides-Pfenex 4/13 Betaseron global #msg-87014470
MRK-Samsng/BIIB 2/13 @ unspecified #msg-84781042, #msg-69629103
Catalent-UMN 12/12 various Asia #msg-82556713
Merck KGaA-RDY 6/12 oncology global #msg-76359649
Daiichi-Coherus 5/12 * Asia #msg-75397629
Fujifilm-Kyowa 3/12 Humira unspecified #msg-73800486
ACT-Bioton 2/12 insulin US & Europe #msg-74987123
ACT-AMGN 12/11 † global #msg-70097496, #msg-84340328
BAX-MNTA 12/11 ‡ global #msg-70212854, #msg-70258421
HSP-Celltrion 10/09 z global #msg-84519981, #msg-77816122
MYL-Biocon 6/09 x global #msg-72421544, #msg-84561737
Procognia-UTR n/a Humira unspecified #msg-84340976
*Enbrel and Rituxan.
†Humira, Remicade, Herceptin, Avastin, Rituxan, Erbitux; excludes AMGN FoB’s for AMGN’s branded drugs.
‡Three products in development: 2 auto-immune and 1 oncology—my guesses are Humira, Orenica, Erbitux; may include up to 6 products eventually.
@ Samsung/BIIB subordinate collaboration known as Samsung Bioepis; Rituxan program terminated (#msg-80622249); presumably excludes FoB’s for BIIB’s branded drugs.
#Humira, Rituxan, Avastin, Herceptin.
x Nine products: Herceptin, Neulasta, Avastin, Humira, Enbrel, Lantus, Novolog, Humalog, one undisclosed.
y Rituxan program terminated (#msg-80236315); status of other programs unknown.
z Each company received a distinct EU/CHMP approval for Remicade on 6/28/13; partnership includes seven (other) products: Rituxan, Herceptin, Enbrel, Erbitux, Synagis, Humira, Avastin.
AI
